{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:04:29Z","timestamp":1791345869003,"version":"4.3.1"},"reference-count":42,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The University of Sydney, Australia","award":["Sydney Research Excellence Initiative 2020"],"award-info":[{"award-number":["Sydney Research Excellence Initiative 2020"]}]},{"name":"The MOG Project","award":["Apollo Grant"],"award-info":[{"award-number":["Apollo Grant"]}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Australia","doi-asserted-by":"publisher","award":["20-0000000025"],"award-info":[{"award-number":["20-0000000025"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1193648"],"award-info":[{"award-number":["GNT1193648"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1196380"],"award-info":[{"award-number":["GNT1196380"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2008339"],"award-info":[{"award-number":["GNT2008339"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2016841"],"award-info":[{"award-number":["GNT2016841"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,1,7]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently no biomarker predictive of disease course. We aim to determine whether MOG-IgG epitopes can predict a relapsing course in MOGAD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MOG-IgG-seropositive confirmed adult MOGAD patients were included (n=202). Serum MOG-IgG and epitope binding were determined by validated flow cytometry live cell-based assays. Associations between epitopes, disease course, clinical phenotype, Expanded Disability Status Scale and Visual Functional System Score at onset and last review were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 202 MOGAD patients, 150 (74%) patients had MOG-IgG that recognised the immunodominant proline42 (P42) epitope and 115 (57%) recognised histidine103\/serine104 (H103\/S104). Fifty-two (26%) patients had non-P42 MOG-IgG and showed an increased risk of a relapsing course (HR 1.7; 95%\u2009CI 1.15 to 2.60, p=0.009). Relapse-freedom was shorter in patients with non-P42 MOG-IgG (p=0.0079). Non-P42 MOG-IgG epitope status remained unchanged from onset throughout the disease course and was a strong predictor of a relapsing course in patients with unilateral optic neuritis (HR 2.7, 95%\u2009CI 1.06 to 6.98, p=0.038), with high specificity (95%, 95%\u2009CI 77% to 100%) and positive predictive value (85%, 95%\u2009CI 45% to 98%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-P42 MOG-IgG predicts a relapsing course in a significant subgroup of MOGAD patients. Patients with unilateral optic neuritis, the most frequent MOGAD phenotype, can reliably be tested at onset, regardless of age and sex. Early detection and specialised management in these patients could minimise disability and improve long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2023-332851","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T13:25:39Z","timestamp":1706621139000},"page":"544-553","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease"],"prefix":"10.1136","volume":"95","clinical-trial-number":[{"clinical-trial-number":"nct05271409","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05063162","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ganesha","family":"Liyanage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P","family":"Trewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Tea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Merheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona X Z","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena J","family":"Fabis-Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Buckland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Fok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-8864","authenticated-orcid":false,"given":"Michael H","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0169-3350","authenticated-orcid":false,"given":"Stephen W","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseel","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-4016","authenticated-orcid":false,"given":"Allan G","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-4307","authenticated-orcid":false,"given":"Simon A","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-1826","authenticated-orcid":false,"given":"Russell C","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0294-9768","authenticated-orcid":false,"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-2276","authenticated-orcid":false,"given":"Fabienne","family":"Brilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2025032210451037000_95.6.544.1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00218-0"},{"key":"2025032210451037000_95.6.544.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8"},{"key":"2025032210451037000_95.6.544.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.12.004"},{"key":"2025032210451037000_95.6.544.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0112-x"},{"key":"2025032210451037000_95.6.544.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000101"},{"key":"2025032210451037000_95.6.544.6","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a Demyelination phenotype and affect Oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"2025032210451037000_95.6.544.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21916"},{"key":"2025032210451037000_95.6.544.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J Neuroinflammation"},{"key":"2025032210451037000_95.6.544.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm1488"},{"key":"2025032210451037000_95.6.544.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8583-z"},{"key":"2025032210451037000_95.6.544.11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"2025032210451037000_95.6.544.12","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13703"},{"key":"2025032210451037000_95.6.544.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"2025032210451037000_95.6.544.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880"},{"key":"2025032210451037000_95.6.544.15","doi-asserted-by":"crossref","first-page":"577467","DOI":"10.1016\/j.jneuroim.2020.577467","article-title":"Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders","volume":"351","author":"Akaishi","year":"2021","journal-title":"J Neuroimmunol"},{"key":"2025032210451037000_95.6.544.16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG\u2013associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025032210451037000_95.6.544.17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315998"},{"key":"2025032210451037000_95.6.544.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30488-0"},{"key":"2025032210451037000_95.6.544.19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/13524585231172954","article-title":"Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes","volume":"29","author":"Reindl","year":"2023","journal-title":"Mult Scler"},{"key":"2025032210451037000_95.6.544.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330237"},{"key":"2025032210451037000_95.6.544.21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ana.26731","article-title":"Do early relapses predict the risk of long\u2010term relapsing disease in an adult and paediatric cohort with MOGAD","volume":"94","author":"Chen","year":"2023","journal-title":"Ann Neurol"},{"key":"2025032210451037000_95.6.544.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody\u2013associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025032210451037000_95.6.544.23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jalm\/jfab101","article-title":"Validation of a flow cytometry live cell-based assay to detect myelin oligodendrocyte glycoprotein antibodies for clinical diagnostics","volume":"7","author":"Lopez","year":"2022","journal-title":"J Appl Lab Med"},{"key":"2025032210451037000_95.6.544.24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025032210451037000_95.6.544.25","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025032210451037000_95.6.544.26","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001027","article-title":"Differential binding of autoantibodies to MOG Isoforms in inflammatory demyelinating diseases","volume":"8","author":"Schanda","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025032210451037000_95.6.544.27","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"2025032210451037000_95.6.544.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301296"},{"key":"2025032210451037000_95.6.544.29","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1200961","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease according to their epitopes","volume":"14","author":"Seok","year":"2023","journal-title":"Front Neurol"},{"key":"2025032210451037000_95.6.544.30","doi-asserted-by":"crossref","first-page":"101939","DOI":"10.1016\/j.msard.2020.101939","article-title":"Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases","volume":"40","author":"Kim","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2025032210451037000_95.6.544.31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005560"},{"key":"2025032210451037000_95.6.544.32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-317969"},{"key":"2025032210451037000_95.6.544.33","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025032210451037000_95.6.544.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"key":"2025032210451037000_95.6.544.35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jnc.15549","article-title":"Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody\u2010associated disease: correlation with relapses and seizures","volume":"160","author":"Luo","year":"2022","journal-title":"J Neurochem"},{"key":"2025032210451037000_95.6.544.36","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025032210451037000_95.6.544.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69182-w","article-title":"Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases","volume":"10","author":"Saxena","year":"2020","journal-title":"Sci Rep"},{"key":"2025032210451037000_95.6.544.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679770","article-title":"Regulatory T cells increase after Rh-MOG stimulation in non-relapsing but decrease in relapsing MOG antibody-associated disease at onset in children","volume":"12","author":"Horellou","year":"2021","journal-title":"Front Immunol"},{"key":"2025032210451037000_95.6.544.39","doi-asserted-by":"crossref","first-page":"577361","DOI":"10.1016\/j.jneuroim.2020.577361","article-title":"Serum level of IL-1\u0392 in patients with inflammatory demyelinating disease: marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD)","volume":"348","author":"Kwon","year":"2020","journal-title":"J Neuroimmunol"},{"key":"2025032210451037000_95.6.544.40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122942"},{"key":"2025032210451037000_95.6.544.41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab105"},{"key":"2025032210451037000_95.6.544.42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00119","article-title":"Effects of the positive threshold and data analysis on human MOG antibody detection by live flow cytometry","volume":"11","author":"Tea","year":"2020","journal-title":"Front Immunol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-332851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T13:49:42Z","timestamp":1742651382000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-332851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,14]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jnnp-2023-332851"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-332851","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]}}}